Jaydess

Levonorgestrel, the active ingredient in Jaydess, is a progestin presented as a 13.5 mg intrauterine system for intrauterine use. It prevents pregnancy and may be used to manage heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Jaydess as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jaydess, a levonorgestrel‑releasing intrauterine system, is used within the hormonal contraceptive pathway for the following clinical indications: - Contraception: provides highly effective, long‑term prevention of pregnancy for up to three years. - Heavy menstrual bleeding: reduces menstrual blood loss and can improve anemia in women with dysfunctional uterine bleeding (off‑label in some regions).

Levonorgestrel IUS may be associated with a range of adverse reactions, most of which are mild and resolve spontaneously.

Common Side Effects: - Irregular bleeding: spotting or breakthrough bleeding during the first months. - Amenorrhea: absence of menstrual periods after initial adjustment. - Pelvic pain or cramping: mild discomfort around the uterus.

Serious or Rare Side Effects: - Uterine perforation: possible during insertion, may need surgical management. - Expulsion: device may be partially or fully expelled, requiring re‑insertion. - Infection: pelvic inflammatory disease or endometritis associated with the procedure.

Before prescribing Jaydess, clinicians should consider several safety measures. - Patient selection: confirm no current pregnancy and assess uterine size and shape. - Contraindications: avoid in women with active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel. - Insertion timing: place within 5 days of menstrual onset or after confirmed negative pregnancy test. - Follow‑up: schedule pelvic exam 4–6 weeks post‑insertion to verify placement. - Device removal: plan removal after approved duration (up to 3 years) or earlier if complications arise. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and direct sunlight.

Levonorgestrel IUS may interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - CYP3A4 inducers: drugs such as rifampicin, carbamazepine, or phenytoin may reduce levonorgestrel effectiveness. - Strong CYP3A4 inhibitors: agents like ketoconazole can increase systemic exposure, though clinical relevance is low for intrauterine delivery.

Moderate Interactions (Monitor Closely): - Antiretroviral therapy: certain protease inhibitors may alter hormone levels; monitor for breakthrough bleeding. - Herbal supplements: St. John’s wort may decrease efficacy; advise patients to discuss use. - Prolonged broad‑spectrum antibiotics: generally safe, but review if therapy exceeds several weeks.